Look up one drug

Exceptional Access criteria on record are for Brand(s): Avandia; DOSAGE FORM/ STRENGTH: 2 mg, 4 mg, 8 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Rosiglitazone Brand(s): Avandia DOSAGE FORM/ STRENGTH: 2 mg, 4 mg, 8 mg tablet For the treatment of type 2 diabetes mellitus in patients with: • Inadequate glycemic control (HbA1c >7%) from ALL other oral antidiabetic agents* funded through one of the Ontario Drug Benefit Programs, in monotherapy or in combination OR • Where ALL other oral antidiabetic agents are inappropriate due to contraindications or intolerance AND • The patient has refused or is not able to take insulin AND • There is no known contraindication to rosiglitazone * Oral antidiabetics include the following agents;  glyburide  metformin  gliclazide (Diamicron, Diamicron MR)  sitagliptin (Januvia)  saxagliptin (Onglyza)  repaglinide (GlucoNorm)  pioglitazone (Actos) Note: A trial with acarbose is not a mandatory requirement. Note: It is not necessary for patients to have tried the following oral antidiabetic agents that are currently not funded by the OPDP for the purposes of obtaining rosiglitazone:  glimepiride (Amaryl)  nateglinide (Starlix) Duration of Approval: 5 years Renewals will be considered where patients have benefited and continue to benefit from rosiglitazone treatment as demonstrated by recent HbA1c levels ≤7% while on treatment with rosiglitazone AND in those who continue to have no known contraindication(s) to rosiglitazone. Duration of Approval: 5 years 36  EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 36, record 17, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access criteria on record are for Brand(s): Avandia; DOSAGE FORM/ STRENGTH: 2 mg, 4 mg, 8 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Rosiglitazone Brand(s): Avandia DOSAGE FORM/ STRENGTH: 2 mg, 4 mg, 8 mg tablet For the treatment of type 2 diabetes mellitus in patients with: • Inadequate glycemic control (HbA1c >7%) from ALL other oral antidiabetic agents* funded through one of the Ontario Drug Benefit (ODB) Programs, in monotherapy or in combination OR • Where ALL other oral antidiabetic agents are inappropriate due to contraindications or intolerance AND • The patient has refused or is not able to take insulin AND • There is no known contraindication to rosiglitazone. * Oral antidiabetics that need to be tried prior to consideration of rosiglitazone include the following agents currently reimbursed through the Ontario Public Drug Programs;  glyburide  metformin  gliclazide (Diamicron, Diamicron MR)  sitagliptin (Januvia)  repaglinide (GlucoNorm)  pioglitazone (Actos)  saxagliptin (Onglyza) Note: A trial with acarbose is not a mandatory requirement. Note: It is not necessary for patients to have tried the following oral antidiabetic agents that are currently not funded by the Ontario Public Drug Programs for the purposes of obtaining rosiglitazone: Standard Approval Duration: 5 years 472 Rosiglitazone Brand(s): Avandia DOSAGE FORM/ STRENGTH: 1 mg, 4 mg, 8 mg tablet Renewals will be considered where patients have benefited and continue to benefit from rosiglitazone treatment as demonstrated by achieving adequate glycemic control. This is shown by a recent HbA1c levels ≤7% while on treatment with rosiglitazone AND in who continue to have no known contraindication(s) to rosiglitazone. Standard Approval Duration: 5 years Palliative Care Medications NOTE: Specific products used to treat ODB-eligible patients undergoing palliative care are reimbursed under the Ontario Public Drug Programs, as Limited use benefits on the ODB formulary or through the Facilitated Access process. Under this process, a select group of participating physicians and nurse practitioners are exempt from obtaining approval under EAP on a case-by-case basis. This assumes that the prescriber has met the qualifications set by their professional associations who administer the enrollment of their members. The prescriber’s license number with their regulatory body must appear on the prescription, for purposes of verification. Palliative Care medication claims to be reimbursed by the ODB program must be prescribed in accordance with the following patient eligibility criteria: “This patient has a progressive, life-limiting illness and has chosen outpatient palliative treatment. Life expectancy of one year is applied to request durations. In order to participate in the Facilitated Access to Palliative Care Drugs process, these prescribers must be registered with their professional association as meeting the qualifications for pCFA enrollement.. For physicians this is by the Ontario Medical Association (“OMA”) and must meet pre-defined criteria the OMA sets. For nurse practitioners, this may be the NPAO or the Nurse practitioners Association of Ontario (NPAO) or the RNAO, th Registered Nurse Association of Ontario. To facilitate the reimbursement process at the pharmacy, these prescribers are asked to indicate either, “Palliative” or “P.C.F.A.” on the prescription. Prescribers who are not registered through this process must obtain approval through the Exceptional Access Program. A prescriber must provide the details of the patient’s diagnosis, current clinical status, and life expectancy. For further information regarding the list of physicians and/or the criteria physicians require to be included on the list, please contact the Ontario Medical Association: (416) 340-2234, or via email. The following products can be reimbursed for the management of patients receiving palliative care through the Telephone Request Service. Note that many Palliative Care drugs have tranoptsitioned to the ODB formulary for funding under Limited Use and do not require EAP authorization. treat ODB- 473  EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 472, record 311, corpus 2025-01-01; name match only, not an eligibility decision

Rosiglitazone · DIN 02403382 Manufacturer: A A Pharma Inc.; listing date 2017-02-28 Health Canada: Marketed since 2019-09-17 · brand ROSIGLITAZONE · ATC A10BG02 ROSIGLITAZONE · form Tablet · route Oral · ingredients ROSIGLITAZONE (ROSIGLITAZONE MALEATE) 8 MG · company Aa pharma inc · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02403382). DIN 02403382: Rosiglitazone Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 682002018; group id 753; item number 1848; lccId None; manufacturer id AAP Source form: Tab; strength: 8mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $2.7452; ministry $2.7452 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02403382 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88819

Interchangeable products

Avandia · DIN 02241114 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02403382

Shortage record checked 2026-09-13T08:10:21.292534+00:00